Trial site
Zurich
Zurich, 8091, SwitzerlandNot linked to an institution yet
- 15running trials
- 13closed trials
The trials here
What the 28 trials at this site are about, from their registry records.
- Phase
- Phase 314 trials
- Phase 25 trials
- Phase 1/24 trials
- Phase 12 trials
- Phase 41 trial
- Status
- Active, not recruiting13 trials
- Completed9 trials
- Terminated3 trials
- Recruiting2 trials
- Withdrawn1 trial
- Lead sponsor
- Novartis Pharmaceuticals28 trials
Running trials
Active, not recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
NCT06617793· Phase 1/2· Novartis Pharmaceuticals· Source
Active, not recruiting
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)
NCT06799000· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)
NCT06675864· Phase 1/2· Novartis Pharmaceuticals· Source
Active, not recruiting
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
NCT06655896· Phase 2· Novartis Pharmaceuticals· Source
Recruiting
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.
NCT05201066· Phase 2· Novartis Pharmaceuticals· Source
Active, not recruiting
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD
NCT05399992· Novartis Pharmaceuticals· Source
Active, not recruiting
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
NCT05415072· Phase 1/2· Novartis Pharmaceuticals· Source
Active, not recruiting
A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent.
NCT05109728· Phase 1· Novartis Pharmaceuticals· Source
Active, not recruiting
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
NCT04857372· Phase 1· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma
NCT04417621· Phase 2· Novartis Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error